Monday, December 4, 2000
With new data showing the equivalence of 30 mg and 60 mg once weekly injections of its Avonex
interferon beta-1a to treat multiple sclerosis, Biogen Inc. argues that it has
demonstrated that higher doses of interferon do not confer additional clinical benefit.
But competitor Serono S.A. maintains that more drug, more often, is still the way to go.
BGEN (Cambridge, Mass.) last week reported on a European study of 802
relapsing MS patients receiving weekly intramuscular injections of either 30 or 60 m